▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1325 by analyst upside · 2026-09-28
BHVN
Biohaven Ltd.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+63.7%
implied upside to consensus target
Current Price $12.99
Consensus Target $21.27
Bull Target $42.0
Bear Target $10.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
8
Hold
4
Sell
0
52-Week Low $7.48
52-Week High $18.57
YTD Return +19.8%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.55
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $7.48
52-Week High $18.57
Current Price $12.99
Bear Target $10.0
Bull Target $42.0
● Now $12.99 ● Target $21.27
TRADING DATA
Avg Volume 2.8M
YTD Return +19.8%
Analyst Count 15
Consensus Buy
Upside to Target +63.7%
Last Updated 2026-09-28

ANALYST SUMMARY

Biohaven Ltd. (BHVN) is currently trading at $12.99 with a Wall Street consensus price target of $21.27, implying potential upside of 63.7% over the next 12 months. 15 analysts currently cover BHVN, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $42.0, while the most cautious has a target of $10.0.

BHVN operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 19.8% year-to-date and is currently trading near the lower end of its 52-week range of $7.48 – $18.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADMA +81.2%
ADMA Biologics, Inc.
$2B · P/E 13.4x · Buy
PBH +45.5%
Prestige Consumer Healthcare Inc.
$2B · P/E 13.1x · Buy
INVA +68.8%
Innoviva, Inc.
$1B · P/E 4.8x · Buy
ANIP +42.9%
ANI Pharmaceuticals, Inc.
$2B · P/E 16.1x · Buy
NUTX +30.9%
Nutex Health Inc.
$2B · P/E 8.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BHVN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Neutral → Neutral 2026-09-10 31% win rate (48 calls)
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2026-09-08 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-08-12 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-11 Building track record
B of A Securities ↓ Downgrade
Neutral → Underperform 2026-06-29 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2026-05-26 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-05-13 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →